BIOVECTRA
11 Aviation Avenue, Charlottetown, PE C1E 0A1
Canada
T: (866) 883-2872
E: solutions@biovectra.com
W: https://www.biovectra.com/
LinkedIn: https://www.linkedin.com/company/biovectra-inc-/
Twitter: https://twitter.com/BIOVECTRA

BIOVECTRA
We care about making better therapeutics.

BIOVECTRA is a full-service CDMO specializing in the clinical-to-commercial scale production of high-quality regulated APIs and intermediates, including biologics, synthetic small molecules, pDNA and mRNA, highly potent APIs, and bioreagents. Our teams leverage decades of expertise and a proven track record of excellence to optimize, adapt, and perfect innovative technologies and drug substance development approaches to deliver world-class solutions for pharmaceutical manufacturing.

• Over 50 years of pharmaceutical manufacturing experience
• Flexible, creative systems designed to deliver solutions quickly and efficiently
• Extensive regulatory expertise backed by long standing relationships with major regulatory bodies

Our Facilities:

• 8 cGMP facilities in Atlantic Canada​
• 270,000+ sq ft manufacturing facility​
• 118,000 L of chemical reactor space​
• 64,000 L of fermentation bioreactor capacity

NEW!  BIOVECTRA Launches Specialized Capabilities in mRNA Drug Product Development & Biomanufacturing BIOVECTRA is accepting projects at its new state-of-the-art biomanufacturing centre located in Prince Edward Island, Canada. The facility features 36,000 square feet of cGMP manufacturing space for mRNA, pDNA and lipid nanoparticle formulation, vaccine and therapeutic production capacity for 160 million doses per year, and fill/finish capacity for 70 million doses per year for commercial distribution.The Biomanufacturing Centre has the unique ability to offer clients end-to-end capabilities for their nucleic acid needs – everything from our own pDNA platform to filled vials.

Learn more at www.BIOVECTRA.com.